Effect of Increased Potassium Intake on Adrenal Cortical and Cardiovascular Responses to Angiotensin II: A Randomized Crossover Study

What Was Tested

Researchers studied Angiotensin II in this randomized controlled trial publication.

Besides its well-described renal effects, aldosterone is also believed to have vascular effects, acting through mineralocorticoid receptors present in endothelial and vascular smooth muscle cells, although mineralocorticoid receptors-independent actions are also thought to be involved.

At the end of each treatment period, the researchers measured potassium and aldosterone in plasma and performed an angiotensin II (AngII) infusion experiment, during which the researchers assessed the aldosterone response in plasma.

Who Took Part

According to the abstract, 25 men were involved.

By PubMed's age tags, the people studied were young adults, adults and middle-aged adults, both men and women.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

Because people in this Angiotensin II study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

As a double-blind Angiotensin II study, the assignments were hidden from both participants and investigators until the end.

A placebo (an inactive look-alike) gave the Angiotensin II group a baseline to be compared against.

In the crossover set-up each of the men took both Angiotensin II and the comparison in turn, acting as their own control.

What Was Measured

At the end of each treatment period, the researchers measured potassium and aldosterone in plasma and performed an angiotensin II (AngII) infusion experiment, during which the researchers assessed the aldosterone response in plasma.

PubMed files the paper under topics including Aldosterone, Angiotensin II, Biomarkers, Blood Pressure, Healthy Volunteers, Hypertension and Potassium.

Author keywords: hemodynamics.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Angiotensin II in 25 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2021 (Journal of the American Heart Association), a journal based in England.

More context: the Angiotensin II compound page, all human trials.